RU2021135116A - Штамм Akkermansia muciniphila и его применение - Google Patents
Штамм Akkermansia muciniphila и его применение Download PDFInfo
- Publication number
- RU2021135116A RU2021135116A RU2021135116A RU2021135116A RU2021135116A RU 2021135116 A RU2021135116 A RU 2021135116A RU 2021135116 A RU2021135116 A RU 2021135116A RU 2021135116 A RU2021135116 A RU 2021135116A RU 2021135116 A RU2021135116 A RU 2021135116A
- Authority
- RU
- Russia
- Prior art keywords
- strain
- metabolic disorders
- snug
- normalizing
- akkermansia muciniphila
- Prior art date
Links
- 241000702462 Akkermansia muciniphila Species 0.000 title claims 9
- 208000030159 metabolic disease Diseases 0.000 claims 12
- 230000036528 appetite Effects 0.000 claims 8
- 235000019789 appetite Nutrition 0.000 claims 8
- 239000006228 supernatant Substances 0.000 claims 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000004930 Fatty Liver Diseases 0.000 claims 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000010706 fatty liver disease Diseases 0.000 claims 3
- 235000001497 healthy food Nutrition 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims 3
- 239000000047 product Substances 0.000 claims 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 3
- 108020004465 16S ribosomal RNA Proteins 0.000 claims 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 210000003486 adipose tissue brown Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000003880 negative regulation of appetite Effects 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21102—C-terminal processing peptidase (3.4.21.102)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Claims (11)
1. Штамм Akkermansia muciniphila SNUG-61027 (номер доступа KCTC 13530BP).
2. Штамм Akkermansia muciniphila SNUG-61027 (номер доступа KCTC 13530BP) по п. 1, причем штамм содержит 16S рДНК, состоящую из нуклеотидной последовательности с SEQ ID NO: 1.
3. Фармацевтическая композиция для подавления аппетита или предупреждения, нормализации или лечения нарушений метаболизма, содержащая штамм Akkermansia muciniphila SNUG-61027 по п. 1 или культуральный раствор, супернатант, экстракт или фракцию этого штамма в качестве действующего вещества.
4. Фармацевтическая композиция для подавления аппетита или предупреждения, нормализации или лечения нарушений метаболизма по п. 3, причем нарушением метаболизма являются нарушение толерантности к глюкозе, диабет, артериосклероз, гиперлипидемия, гиперхолестеринемия, жировая дегенерация печени, сердечно-сосудистые заболевания или ожирение.
5. Фармацевтическая композиция для подавления аппетита или предупреждения, нормализации или лечения нарушений метаболизма по п. 3, при этом штамм Akkermansia muciniphila SNUG-61027, или культуральный раствор, супернатант, экстракт или фракция этого штамма, вызывает любое из следующего: повышение уровня IL-6, повышение секреции GLP-1 или повышение активности бурого жира.
6. Продукт здорового питания для подавления аппетита или нормализации или облегчения состояния при нарушениях метаболизма, содержащий штамм Akkermansia muciniphila SNUG-61027 по п. 1 или культуральный раствор, супернатант, экстракт или фракцию этого штамма в качестве действующего вещества.
7. Продукт здорового питания для подавления аппетита или нормализации или облегчения состояния при нарушениях метаболизма по п. 6, причем нарушением метаболизма являются нарушение толерантности к глюкозе, диабет, артериосклероз, гиперлипидемия, гиперхолестеринемия, жировая дегенерация печени, сердечно-сосудистые заболевания или ожирение.
8. Продукт здорового питания для подавления аппетита или нормализации или облегчения состояния при нарушениях метаболизма по п. 6, при этом штамм Akkermansia muciniphila SNUG-61027, или культуральный раствор, супернатант, экстракт или фракция этого штамма, вызывает любое из следующего: повышение уровня IL-6, повышение секреции GLP-1 или повышение активности бурого жира.
9. Использование штамма Akkermansia muciniphila SNUG-61027 (номер доступа KCTC 13530BP) или культурального раствора, супернатанта, экстракта или фракции этого штамма для подавления аппетита или предупреждения, лечения, нормализации или улучшения состояния при нарушениях метаболизма.
10. Использование для подавления аппетита или предупреждения, лечения, нормализации или улучшения состояния при нарушениях метаболизма по п. 9, причем штамм Akkermansia muciniphila SNUG-61027 (номер доступа KCTC 13530BP) содержит 16S рДНК, содержащую нуклеотидную последовательность с SEQ ID NO: 1.
11. Использование для подавления аппетита, нормализации или облегчения состояния при нарушениях метаболизма по п. 9, причем нарушением метаболизма являются нарушение толерантности к глюкозе, диабет, артериосклероз, гиперлипидемия, гиперхолестеринемия, жировая дегенерация печени, сердечно-сосудистые заболевания или ожирение.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR0-2018-0121137 | 2018-10-11 | ||
| KR10-2018-0121137 | 2018-10-11 | ||
| KR20180121137 | 2018-10-11 | ||
| KR1020190125670A KR102197180B1 (ko) | 2018-10-11 | 2019-10-10 | 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물 |
| KR10-2019-0125670 | 2019-10-10 | ||
| KR0-2019-0125670 | 2019-10-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021112440A Division RU2777068C1 (ru) | 2018-10-11 | 2019-10-11 | Штамм Akkermansia muciniphila и его применение |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2021135116A true RU2021135116A (ru) | 2021-12-06 |
| RU2021135116A3 RU2021135116A3 (ru) | 2022-04-29 |
| RU2792651C2 RU2792651C2 (ru) | 2023-03-22 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| JP7185036B2 (ja) | 2022-12-06 |
| EP3865568A4 (en) | 2022-08-17 |
| CN113330109A (zh) | 2021-08-31 |
| KR20200041280A (ko) | 2020-04-21 |
| JP2022502067A (ja) | 2022-01-11 |
| AU2019356410B2 (en) | 2023-07-06 |
| RU2021135116A3 (ru) | 2022-04-29 |
| BR112021006855A2 (pt) | 2021-08-10 |
| EP3865568A2 (en) | 2021-08-18 |
| CA3115196A1 (en) | 2020-04-16 |
| AU2019356410A1 (en) | 2021-06-03 |
| KR102197180B1 (ko) | 2020-12-31 |
| MX2021004056A (es) | 2021-06-04 |
| CN113330109B (zh) | 2024-02-09 |
| US20220002665A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019356410B2 (en) | Akkermansia muciniphila strain and use thereof | |
| EP2546330B1 (en) | Lactic acid bacterium-containing preparation | |
| JP6864784B2 (ja) | ラクトバチルス・ラムノサスｌｍ１０１９菌株およびこれを含む肥満または糖尿病の予防および治療用の組成物 | |
| TW202136495A (zh) | 胚芽乳酸桿菌菌株及包括其之用於預防或治療代謝疾病的組成物 | |
| JP2019535828A5 (ru) | ||
| RU2015129066A (ru) | Применение bifidobacterium animalis для лечения или предотвращения набора веса и инсулинорезистентности | |
| WO2020076136A3 (ko) | 아커만시아 뮤시니필라 균주 및 이의 용도 | |
| WO2018093238A3 (ko) | 포름산 생성능이 우수한 균주를 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물 | |
| KR20230113240A (ko) | 락토바실러스 퍼멘텀 균주 및 이를 포함하는 대사질환의예방 또는 치료용 조성물 | |
| KR20210039961A (ko) | 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법 | |
| KR20190043885A (ko) | 락토바실러스 사케이 Probio-65 또는 그의 추출물을 포함하는 당뇨병의 예방 또는 치료용 조성물 | |
| JP2016088845A (ja) | 抗疲労及び免疫増進用食品組成物 | |
| WO2018093237A3 (ko) | 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물 | |
| WO2011081424A3 (ko) | 통풍 개선 효과가 있는 기능성식품과, 김치, 고추장, 된장, 간장 등의 기능성 발효식품 및 그 제조방법 | |
| WO2010090407A3 (en) | A composition comprising an extract of puerariae radix showing immune enhancing activity and the use thereby | |
| CN112369608A (zh) | 一种含有海洋寡糖的减肥食品 | |
| CN109965290B (zh) | 改善肠道菌群代餐粉及其应用 | |
| JP2013063956A (ja) | Ｇｌｐ−１分泌促進剤 | |
| Lee et al. | Anti-obesity effect of Aster yomena ethanol extract in high fat diet-induced obese mice | |
| CN105079102A (zh) | 一种预防心脑血管疾病发生的制剂及其制备方法 | |
| Laksmitawati et al. | Activity of porang flour and moringa extract to blood glucose and lipid levels in alloxan induced diabetic mice | |
| JP2018135311A (ja) | Ｆｇｆ２１発現促進用組成物 | |
| CN109045045B (zh) | 一种治疗心脑血管疾病的中药活性成分组合物 | |
| CN102388971A (zh) | 一种复方牛初乳粉 | |
| Ghatani et al. | Hypolipidemic and hypoglycemic nature of lactobacillus strains in fermented vegetable and dairy products |